Arcturus Therapeutics Holdings Inc. (ARCT)
|52 Week Range||11.7-31.41|
|1y Target Est||-|
|DCF Unlevered||ARCT DCF ->|
|DCF Levered||ARCT LDCF ->|
|Debt / Equity||66.62%||Buy|
Upgrades & Downgrades
Latest ARCT news
Why Arcturus Therapeutics Stock Is Soaring Today
29 March 2023
Arcturus beat expectations with its Q4 results. The company also provided an encouraging update on its pipeline programs.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call Transcript
28 March 2023
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine - ...
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates
28 March 2023
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto...
Arcturus' mRNA Platform: The Future Of Quick And Efficient Vaccine Delivery
1 February 2023
Arcturus is revolutionizing biotechnology with its cutting-edge mRNA vaccines and delivery systems. They recently teamed up with CSL Seqirus, a leading player in the flu vaccine industry.
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
19 December 2022
SAN DIEGO--( BUSINESS WIRE )--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of ...
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
9 November 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Kyle Gutsadt - Investor Relations Joseph Payne - President and Chief...
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates
9 November 2022
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...
Arcturus Therapeutics to Present at the Following Investor Conferences in November
7 November 2022
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of i...
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
4 November 2022
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >